LEADER 05188nam 22006614a 450 001 996211665003316 005 20240410062420.0 010 $a1-280-27291-0 010 $a9786610272914 010 $a0-470-23708-2 010 $a0-471-68673-5 010 $a0-471-68674-3 035 $a(CKB)1000000000018943 035 $a(EBL)221303 035 $a(OCoLC)475926347 035 $a(SSID)ssj0000129652 035 $a(PQKBManifestationID)11141434 035 $a(PQKBTitleCode)TC0000129652 035 $a(PQKBWorkID)10079246 035 $a(PQKB)10282588 035 $a(MiAaPQ)EBC221303 035 $a(Au-PeEL)EBL221303 035 $a(CaPaEBR)ebr10114124 035 $a(CaONFJC)MIL27291 035 $a(EXLCZ)991000000000018943 100 $a20040713h20042004 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aContemporary drug synthesis /$fJie Jack Li [et al.] 205 $a1st ed. 210 1$aHoboken, N.J. :$cWiley-Interscience,$d2004. 210 4$a©2004 215 $a1 online resource (xv, 221 pages) $cillustrations 300 $aDescription based upon print version of record. 311 0 $a0-471-21480-9 320 $aIncludes bibliographical references and index. 327 $aContemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction 327 $a3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References 327 $aChapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 327 $a7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References 327 $aChapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References 330 $aAn integrated and insightful look at successful drug synthesis in today's drug discovery market The pharmaceutical industry is unquestionably vibrant today, with drug synthesis making a vital contribution. Whether in the early developmental stages of identifying and optimizing a lead, or the latter stages of process development and cost-effective scale-up, the ability to design elegant and economical synthetic routes is often a major factor in the eventual viability and commercial success of a drug. 606 $aPharmaceutical chemistry 606 $aDrugs$xDesign 615 0$aPharmaceutical chemistry. 615 0$aDrugs$xDesign. 676 $a615/.31 701 $aLi$b Jie Jack$0440094 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a996211665003316 996 $aContemporary drug synthesis$91507849 997 $aUNISA